No Cure Exists for Dengue; Flavonoids Show Laboratory Promise But Lack Clinical Validation
There is currently no cure for dengue virus infection, and treatment remains entirely supportive—focused on monitoring for shock and hemorrhage 1. While flavonoids and certain Traditional Chinese Medicine (TCM) compounds demonstrate antiviral activity in laboratory studies, none have been validated through rigorous clinical trials for routine clinical use.
Current Standard of Care
The CDC guideline is unequivocal: patients with clinically suspected dengue should receive appropriate management to monitor and treat shock and hemorrhage 1. This means:
- Aggressive fluid resuscitation for shock
- Monitoring platelet counts and hematocrit for hemorrhagic complications
- Supportive care for fever and pain (avoiding NSAIDs due to bleeding risk)
- No specific antiviral therapy exists
Flavonoids: Laboratory Data Without Clinical Translation
In Vitro Evidence
Recent laboratory studies show promising antiviral mechanisms:
- Flavone glycosides (not aglycones) from plants like Scutellaria coccinea and Lippia alba inhibit DENV viral adsorption with IC50 values of 3.0-65 µg/mL 2
- Biflavonoids, particularly sotetsuflavone, inhibit DENV NS5 RNA polymerase with IC50 = 0.16 µM 3
- Baicalin and baicalein from Scutellaria baicalensis show antiviral effects and are entering Phase 1 trials 4
Critical Gap
None of these compounds have demonstrated efficacy in human clinical trials for dengue treatment. The 2025 study 2 and 2026 studies 5, 4, 6 remain at the in vitro or early animal model stage.
Traditional Chinese Medicine: Limited Clinical Evidence
One retrospective cohort study from 2020 examined TCM integration with Western medicine 7:
- Patients receiving TCM formulas (Zhu Ye Shi Gao Tang, Gui Pi Tang) alongside conventional therapy showed differences in hemoglobin and ALT changes
- Major limitation: No control for disease severity, retrospective design, and all patients received standard supportive care
- Cannot establish causation or superiority over supportive care alone
The 2026 review 8 acknowledges TCM's theoretical multi-target approach but provides no Level 1 evidence for clinical efficacy.
Ayurvedic Medicine: Insufficient Evidence
While the 2024 review 9 mentions Carica papaya (papaya leaf extract) showing platelet-enhancing activity in clinical trials, this addresses thrombocytopenia management, not viral cure. The evidence quality remains low, with small sample sizes and methodological limitations.
Clinical Recommendation Algorithm
For any patient with confirmed or suspected dengue:
- Provide supportive care only (fluid management, hemorrhage monitoring)
- Do not recommend flavonoids, TCM, or Ayurvedic preparations as antiviral therapy—no validated clinical efficacy
- Consider papaya leaf extract only for severe thrombocytopenia if conventional platelet support is unavailable (low-quality evidence) 9
- Report cases to public health authorities 1
Common Pitfalls to Avoid
- Do not delay supportive care while pursuing unproven herbal therapies
- Do not use NSAIDs for fever control (bleeding risk)
- Do not assume in vitro antiviral activity translates to clinical benefit—the pharmacokinetics, bioavailability, and tissue distribution of flavonoids in humans remain unestablished
Future Considerations
The baicalin/baicalein Phase 1 trial 4 may eventually provide human safety and efficacy data, but until published clinical trial results demonstrate mortality or morbidity benefit, these remain investigational only.